Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cell therapy cocktail takes on tough lymphoma

NCT ID NCT07125872

Recruiting now Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 31, 2026 · Last updated May 01, 2026 · Updated 2 times

Summary

This study tests a new combination of treatments for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The approach uses specially engineered immune cells (CD19 t-haNK) plus an immune booster (N-803) along with the standard drug rituximab. The goal is to see how many participants' tumors shrink or disappear, and to monitor side effects. About 20 people will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED B-CELL NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Albert Cellular Therapy

    RECRUITING

    Pretoria, 0044, South Africa

    Contact

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Dr. Jackie Thomson Inc

    RECRUITING

    Johannesburg, 2193, South Africa

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RELAPSED B-CELL NON HODGKIN LYMPHOMA RELAPSED B-CELL NON HODGKIN LYMPHOMA